Gamida Cell Receives Breakthrough Therapy Designation For NiCord
Gamida Cell was granted FDA Breakthrough Therapy Designation for NiCord, a novel graft modality for bone marrow transplantation.
On Oct. 11, 2016 Gamida Cell announced that FDA granted NiCord, an in development novel graft modality for bone marrow transplantation in patients with high-risk hematological malignancies, breakthrough therapy designation. In a press announcement, the company said the Phase III registration study of NiCord is planned to begin before the end of the year.
Data from the Pilot and Phase 1/2 studies of NiCord have demonstrated clinically meaningful improvement in time to neutrophil engraftment over cord blood transplantation. NiCord study data have shown fewer infections, reduced length of hospitalization, quicker platelet engraftment, and improved non-relapse mortality when compared with unmanipulated cord blood transplantation.
Source: Gamida Cell
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
